Partnering on a mission
How Brii’s partnering strategy benefits investors and Chinese social good
With a $260 million war chest and a banner roster of execs, advisors and deals, Brii Biosciences is pushing an agenda to bring infectious diseases to the forefront of innovation in China. Its top priority is to leverage digital health data to both further the public health mission and build a sustainable company.
Last week, Arch Venture Partners and a syndicate of Chinese investors launched Brii with a strategy to take innovations developed in the west and develop them in China, Hong Kong, Macau and Taiwan, and in parallel pursue internal programs from Chinese innovations to out-license for development in the west.
Brii is headed by public health advocate and infectious disease expert Zhi Hong, and is using its resources to step outside the standard biotech model by integrating a suite of digital tools -- for data tracking and analysis and patient communication -- across various stages of development.
The company believes the approach will benefit Brii and the social good by facilitating patient education, recruitment and compliance.
“I didn’t want this to be just another start-up with a very narrow view of progressing medicine from Phase I to Phase II. I want to take a bigger picture of the whole patient journey,” Hong told BioCentury.
Hong’s focus is on the full spectrum of patient care. “From when they